. Author manuscript; available in PMC: 2025 Aug 22.

Published in final edited form as: Am J Prev Med. 2025 May 28;69(2):107736. doi: 10.1016/j.amepre.2025.107736

Appendix Table 4.

Characteristics of included studies.

								Relative benefit (95% CI) of all-cause mortality		Relative benefit (95% CI) of lung cancer mortality		Lung cancer mortality risk per 100 000 person-years (95% CI)
Trial (Publication)	Type of Intervention	Country	Sample Size (n)	Age range (years)	Enrollment period	Median pack-years	Median Follow-up (years)	Hazard Ratio (95% CI)	Relative Risk (95% CI)	Hazard Ratio (95% CI)	Relative Risk (95% CI)	Control	Intervention	ARR per 100 000 person-years (95% CI)
NLST (NLST 2019)	Three yearly LDCT screening rounds (vs three yearly single-view CXR)	United States	53452	55–74	2002–2004	48	12.3	Not reported	0.97 (0.94–1.01)	Not reported	0.92 (0.85–1.00)	Person-time not reported	Person-time not reported	Person-time not reported
LUSI (Becker 2020)	Baseline LDCT + four subsequent yearly LDCT screening rounds (vs no screening)	Germany	4052	50–69	2007–2011	Not reported	8.8	0.99 (0.79–1.25)	0.98^a (0.79–1.22)^a	0.74 (0.46–1.19)	0.72^a (0.45–1.16)^a	Person-time not reported	Person-time not reported	Person-time not reported
MILD (Pastorino 2019)	LDCT every 12 months or 24 months (vs no screening)	Italy	4099	49–75	2005	39	10	0.80 (0.62–1.03)	0.94^a (0.73–1.20)^a	0.61 (0.39–0.95)	0.73^a (0.47–1.12)^a	247 (176–336)^a	173 (124–236)^a	73.5 (−17.2–164)^a
NELSON (De Koning 2020)	Baseline LDCT + subsequent LDCT screening at year 1, 3, and 5.5 (vs no screening)	Netherlands	13195 (men only)	50–74	2003–2005	38	10	Not reported	1.01 (0.92–1.11)	Not reported	0.76 (0.61–0.94)	330 (286–378)^a	250 (213–293)^a	79.3 (19.5–139.0)^a
ITALUNG (Paci 2017)	Annual LDCT for 4 years (vs no screening)	Italy	3206	55–69	2004–2006	40	9.3	Not reported	0.83 (0.67–1.03)	Not reported	0.70 (0.47–1.03)	421 (321–542)^a	293 (212–395)^a	128 (−10 to 265)^a
UKLS (Field 2021)	Baseline LDCT only (vs no screening)	United Kingdom	3968	50–75	2011–2013	Not reported	7.3	Not reported	0.91 (0.77–1.09)	Not reported	0.65 (0.41–1.02)	330a (242–441)^a	213a (144–304)^a	117a (−5 to 239)^a
DANTE (Infante 2015)	Baseline LDCT + four subsequent yearly LDCT screening rounds (vs no screening)	Italy	2450	60–74	2001–2006	45	8.35	0.947 (0.769–1.165)	0.96a (0.79–1.16)^a	0.993 (0.688–1.433)	1.01a (0.70–1.44)^a	544 (410–709)	543 (413–700)	1.81 (−198 to 201)^a
DLCST (Wille 2016)	Baseline LDCT + four subsequent yearly LDCT screening rounds (vs no screening)	Denmark	4104	50–70	2004–2006	35	9.80	1.02 (0.82–1.27)	1.01a (0.82–1.25)^a	1.03 (0.66–1.60)	1.03a (0.66–1.60)^a	194 (138–267)^a	200 (143–274)^a	−6.22 (−94.4 to 82.0)^a

Abbreviations: CI=confidence interval; NLST = United States National Lung Screening Trial; LUSI = German Lung Cancer Screening Intervention Trial; MILD = Multicentric Italian Lung Detection Trial; NELSON = Dutch-Belgian Nederlands-Leuvens Longkanker Screenings Onderzoek trial; ITALUNG = Italian Lung Cancer Screening Trial; UKLS = United Kingdom Lung Cancer Screening Trial; DANTE = Italian Detection And screening of early lung cancer by Novel imaging TEchnology trial; DLCST = Danish Lung Cancer Screening Trial.

These values were calculated from published data; all other tabulated values were directly reported by the studies.